Obesity Hypertension

CONDITION

Cardiovascular

GENDER

Both males and females

AGE GROUP

From 25

to 65 years

STATUS

Recruiting

Project Title: Sympathoinhibition as a preferred second line treatment of obesity related hypertension

This research study aims to optimise the treatment of hypertension in individuals with obesity. It will compare the effectiveness of two combinations of medications in lowering blood pressure, and will determine which combination therapy has a more beneficial effect on the symptoms and risk factors associated with obesity.

 

It will utilise 3 types of antihypertensive medications.

  • Perindopril will be used as ‘background’ therapy – you will receive this medication for the duration of the study. This is required so that you are not exposed to risk associated with untreated hypertension.
  • The other 2 treatments: Moxonidine and Amlodipine will be added to this treatment, one at a time to compare their effectiveness in lowering blood pressure and decreasing obesity related symptoms (weight, nerve activity, blood sugar levels etc).

 

If you have the following below, you may be eligible for the trial!

  • BMI≥30kg/m2
  • Diagnosis with hypertension
  • Stable weight over the past 6 months
  • Hidden

Approved By: Human Research Ethics Office, The University of Western Australia              

Clinical Trial Registry Link: